Search

Pexelizumab

It is being investigated by Alexion Pharmaceuticals.

Parsatuzumab

Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)). … Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or

Penimepicycline

It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].

3-amino-5-phenylpentane

This compound belongs to the phenylpropylamines. … These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K

CRA-028129

CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

Clenoliximab

It has investigated for the treatment of rheumatoid arthritis.

SIG-001

SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

Kallidinogenase

XL281

XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.

RO7284755

RO7284755 is under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced And … /or Metastatic Solid Tumors).